-
-
-
-
-
Stem Cell Therapy: 5 Major Challenges
Biotech
Explore the five major challenges in stem cell therapy, including sourcing, immune response, functional heterogeneity, post-transplant viability, and targeted delivery. Learn how these affect clinical outcomes.
-
BioNTech Acquires CureVac in $1.25B mRNA Deal
BioNTech
BioNTech acquires CureVac in a $1.25 billion all-stock deal, expanding its mRNA cancer therapy pipeline and resolving ongoing litigation. The acquisition strengthens BioNTech’s oncology strategy and manufacturing capabilities.
-
Bristol Myers Squibb Bets on ACP3 in $1.35B Deal
BMS
Bristol Myers Squibb teams up with Philochem in a $1.35B radiopharma deal to develop OncoACP3, a novel prostate cancer therapy targeting ACP3, offering a potential alternative to PSMA-focused treatments.
-
-
-
米林县|
雅江县|
卢氏县|
淮阳县|
旌德县|
新河县|
蓬溪县|
靖江市|
青铜峡市|
贵德县|
安化县|
江源县|
米林县|
射阳县|
镇坪县|
杨浦区|
会泽县|
依兰县|
忻城县|
察哈|
顺昌县|
东乡族自治县|
于田县|
分宜县|
彝良县|
滦平县|
高密市|
弥渡县|
富裕县|
铅山县|
防城港市|
晋州市|
临泉县|
天等县|
乃东县|
建平县|
石城县|
澄迈县|
盐池县|
阿尔山市|
义乌市|